BiTE therapy for rheumatoid arthritis.

A pilot study suggests that the bispecific T cell engager blinatumomab may provide a new therapy for patients with refractory rheumatoid arthritis; larger studies and deep phenotyping will be crucial to thoroughly evaluate and optimize this approach.